Heag Pain Management Center PA

Heag Pain Management Center PA was paid $6.14M by Medicaid between Jan 2018 and Nov 2024, across 39 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 43% of everything it billed.

Compared with peers

Next to other Durable Medical Equipment & Medical Supplies providers in North Carolina

Rank by total paid#16 of 780

Median peer was paid$5K

This provider vs. median1,244×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	24,459	$1.18M
2019	16,825	$902K
2020	21,376	$914K
2021	30,799	$926K
2022	22,394	$768K
2023	12,953	$887K
2024incomplete	12,950	$570K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	43%	20,699	13,066	$2.64M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	22%	30,319	17,586	$1.36M
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	14%	35,596	17,461	$875K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	6.8%	5,057	2,885	$419K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	6.3%	16,178	11,379	$386K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.9%	3,419	1,536	$180K
82075		1.6%	11,100	9,397	$98K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	<1%	766	545	$44K
L0631	Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	<1%	243	86	$26K
95165	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials	<1%	194	24	$23K
99454		<1%	821	412	$19K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	344	203	$16K

27 more codes

99457		<1%	827	$15K
99349		<1%	275	$7K
62322		<1%	95	$7K
95004	Percutaneous tests with allergenic extracts, immediate type reaction	<1%	36	$5K
95923		<1%	191	$5K
99203	Doctor's office visit, new patient (routine)	<1%	112	$4K
99458		<1%	160	$3K
99492		<1%	87	$3K
95921		<1%	174	$3K
99493		<1%	76	$2K
99494		<1%	81	$2K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	230	$2K
99072		<1%	8,447	$1K
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	147	$959.64
99453		<1%	154	$678.76
93922		<1%	188	$655.41
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	27	$614.60
93040		<1%	105	$370.42
95924		<1%	18	$102.74
G0447	Face-to-face behavioral counseling for obesity, 15 minutes	<1%	78	$41.20
99401		<1%	47	$14.39
G8427	Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications	<1%	5,001	$0.01
A4246	Betadine or phisohex solution, per pint	0%	127	$0.00
A4245	Alcohol wipes, per box	0%	134	$0.00
A4212	Non-coring needle or stylet with or without catheter	0%	44	$0.00
A4213	Syringe, sterile, 20 cc or greater, each	0%	110	$0.00
S0020	Injection, bupivicaine hydrochloride, 30 ml	0%	49	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGRANT, RANDALL (OFFICE MANAGER)